Researcher:
Gençdal, Genco

Profile Picture
ORCID

Job Title

Doctor

First Name

Genco

Last Name

Gençdal

Name

Name Variants

Gençdal, Genco

Email Address

Birth Date

Filters

2021 - 202310

Advanced Search

Filter by

Settings

Researcher Of Publications: search.filters.isAuthorOfPublication.a3bf3b1a-eead-4377-a3c1-0ac86a3897a6

Search Results

Now showing 1 - 10 of 10
  • Placeholder
    PublicationMetadata only
    Functional cure with lonafarnib-based therapy in chronic hepatitis delta
    (Wiley, 2022) Yurdcu, Esra; Gumussoy, Mesut; Keskin, Onur; Zeybel, Mujdat; Idilman, Ramazan; Bozdayi, Mithat; Choong, Ingrid; Glenn, Jeffrey; Gençdal, Genco; Yurtaydın, Süleyman Cihan; Akyıldız, Murat; Zeybel, Müjdat; Doctor; Faculty Member; Faculty Member; 0000-0001-5440-4623; N/A; School of Medicine; School of Medicine; School of Medicine; Koç University Hospital; N/A; 189330; 123080; 214694
    N/A
  • Placeholder
    PublicationMetadata only
    Editorial: natural history of hepatitis delta virus-induced liver disease - less severe today but still needs attention
    (Wiley, 2021) N/A; N/A; N/A; Gençdal, Genco; Zeybel, Müjdat; Yurtaydın, Süleyman Cihan; Doctor; Faculty Member; Faculty Member; N/A; School of Medicine; School of Medicine; Koç University Hospital; N/A; 214694; 189330
    N/A
  • Placeholder
    PublicationMetadata only
    Chronic hepatitis delta with normal alt and hepatitis d viremia
    (Elsevier, 2022) Arici, Sena; Palom, Adriana; Gumussoy, Mesut; Idilman, Ramazan; Esteban, Rafael; Buti, Maria; Gençdal, Genco; Zeybel, Müjdat; Yurtaydın, Süleyman Cihan; Doctor; Faculty Member; Faculty Member; N/A; School of Medicine; School of Medicine; Koç University Hospital; N/A; 214694; 189330
    N/A
  • Placeholder
    PublicationMetadata only
    Histopathological evaluation of long-term tenofovir disoproxil fumarate treatment in patients with hepatitis be antigen-negative chronic hepatitis B
    (BioMed Central, 2021) Abaylı, Bahri; Abaylı, Cansu; N/A; Gençdal, Genco; Doctor; N/A; Koç University Hospital; N/A
    Background: Hepatitis B virus is a universal health problem. There are approximately 250 million people living with hepatitis B worldwide, and approximately 600000 of these people die every year due to the virus. Aim: to compare the pretreatment and post-treatment histopathological results of patients with hepatitis be antigen (HBeAg)-negative chronic hepatitis B (CHB) who had been receiving tenofovir disoproxil fumarate (TDF) treatment at our clinic for at least 5 years. Methods: patients with HBeAg-negative CHB who were being treated with TDF (245 mg/d) were included in the study. Liver biopsies of patients before TDF treatment and liver biopsies after 5 years of TDF treatment were retrospectively compared. Results: a total of 50 HBeAg-negative CHB patients were included in the study (mean age: 47.9 ± 10.4 years, men: 27.54%). Histological improvement was observed in 78% (39) of the patients after 5 years of treatment. After the 5 years of treatment, the mean Ishak score of the patients was 1.3 ± 1.3, and the mean histologic activity index score was 4.1 ± 2.8. A 1.53 point reduction in Ishak fibrosis score was detected after long-term TDF treatment. Conclusion: liver biopsies after 5 years of TDF treatment revealed a significant histological response and a regression of the necroinflammatory score compared to pretreatment liver biopsies. To better understand the effects of antiviral treatments on the improvement of liver histology, long-term studies involving larger numbers of patients are needed.
  • Placeholder
    PublicationMetadata only
    The course of COVID-19 infection in patients with chronic hepatitis B and Delta
    (Elsevier, 2022) Parlar, Yavuz Emre; Keskin, Onur; Kırmızıgül, Beril; Gümüşsoy, Mesut; İdilman, Ramazan; N/A; Gençdal, Genco; Zeybel, Müjdat; Yurtaydın, Süleyman Cihan; Doctor; Faculty Member; Faculty Member; N/A; School of Medicine; School of Medicine; Koç University Hospital; N/A; 214694; 189330
    N/A
  • Placeholder
    PublicationMetadata only
    Determination of Turkish norms of psychometric tests for diagnosing minimal hepatic encephalopathy and proposal of a high sensitive screening test battery
    (Springer, 2021) Ozbas, Burak; Keskin, Onur; Hecker, Hartmut; Karahan, Irfan; Ozbas, Cansu; Kalkan, Cagdas; Kartal, Aysun; Onder, Fatih Oguz; Oncu, Burcu Kahveci; Gunsar, Fulya; Idilman, Ramazan; Weissenborn, Karin; Ozutemiz, Omer; Gençdal, Genco; Akyıldız, Murat; Yurtaydın, Süleyman Cihan; Doctor; Faculty Member; Faculty Member; N/A; School of Medicine; School of Medicine; Koç University Hospital; N/A; 123080; 189330
    Background Psychometric hepatic encephalopathy score (PHES) needs local standardization. Aims This study aimed at standardizing PHES for Turkish patients and compare them with German norms; to determine minimal hepatic encephalopathy (mHE) prevalence with two different methods [PHES battery and Critical Flicker Frequency (CFF)] and to assess whether sub-tests of the battery can be used for screening for mHE. Methods Healthy volunteers (n = 816; 400 male) and cirrhotics (n = 124; 58 male) were included. For mHE diagnosis PHES score threshold was set at <= - 5 points and that of CFF at < 39 Hz. For comparing German and Turkish norms, datasets were combined. Multiple backward procedure was applied to assess effects of age, sex and education on single tests of the battery. Receiver operating characteristic (ROC) curves were created for assessing diagnostic capabilities of subtests of the battery. Results PHES norms for Turks were developed. MHE prevalence in compensated cirrhotics was 29.8% and 27.4% with PHES and CFF tests, respectively, with low compatibility (kappa coefficient 0.389); mHE prevalence decreased to 16% when both tests were combined. Turks performed worse vs Germans in the digit symbol (DS) and serial dotting (SD) subtests but performed better in other subtests. In ROC analyzes of subtests, the combination of DS + SD tests achieved an AUROC of 0.974 versus PHES. Conclusions Use of two methods for diagnosing mHE is important for research purposes. From a clinical perspective, sensitivity with acceptable specificity may suffice for screening instruments for mHE. Combined use of DS and SD subtests of the PHES battery appears suitable for this purpose.
  • Placeholder
    PublicationMetadata only
    Non-invasive fibrosis markers for assessment of liver fibrosis in chronic hepatitis delta
    (John Wiley and Sons Inc, 2023) Kalkan, Çağdaş; Yılmaz, Yusufcan; Erdoğan, Beyza Doğanay; Savaş, Berna; Yurdcu, Esra; Çalışkan, Aysun; Keskin, Onur; Törüner, Murat; Bozdayi, A. Mithat; Idilman, Ramazan; Yurtaydın, Süleyman Cihan; Gençdal, Genco; Zeybel, Müjdat; Faculty Member; Doctor; Faculty Member; School of Medicine; N/A; School of Medicine; Koç University Hospital; 189330; N/A; 214694
    Assessment of liver fibrosis by non-invasive means is clinically important. Studies in chronic hepatitis delta (CHD) are scarce. We evaluated the performance of eight serum fibrosis markers [fibrosis-4 score (FIB-4), aspartate aminotransferase (AST) to alanine aminotransferase (ALT) ratio (AAR), age-platelet index (API), AST-to platelet-ratio-index (APRI), Goteborg University Cirrhosis Index (GUCI), Lok index, cirrhosis discriminant score (CDS) and Hui score] in CHD and chronic hepatitis B (CHB). Liver stiffness was assessed by transient elastography (TE) in CHD. The ability of fibrosis markers to detect significant fibrosis and cirrhosis were evaluated in 202 CHB and 108 CHD patients using published and new cut-offs through receiver operating characteristics (ROC) analysis. The latter was also applied to obtain cut-offs for TE. APRI, Fib-4, API and Hui score were assessed for significant fibrosis, and APRI, GUCI, Lok index, CDS and AAR for cirrhosis determination. Fibrosis markers displayed weak performance in CHB for significant fibrosis with area under ROC (AUROC) curves between 0.62 and 0.71. They did slightly better for CHD. TE displayed an AUROC of 0.92 and performed better than serum fibrosis markers (p < 0.05 for fibrosis markers). For cirrhosis determination, CDS and Lok Index displayed an AUROC of 088 and 0.89 in CHB and GUCI, Lok index and APRI displayed AUROCs around 0.90 in CHD. TE displayed the best AUROC (0.95). Hence TE is superior to serum fibrosis markers for diagnosing significant liver fibrosis and cirrhosis. GUCI, Lok index and APRI displayed a reasonable performance in CHD, which needs further confirmation.
  • Thumbnail Image
    PublicationOpen Access
    Recommendations for hepatitis B immunoglobulin and antiviral prophylaxis against hepatitis B recurrence after liver transplantation
    (Aves, 2021) Akarsu, Mesut; Önem, Soner; Turan, İlker; Adalı, Gupse; Akdoğan, Meral; Aladağ, Murat; Balaban, Yasemin; Danış, Nilay; Dayangaç, Murat; Gökcan, Hale; Sertesen, Elif; Gürakar, Merve; Harputluoğlu, Murat; Kabacam, Gökhan; Karademir, Sedat; Kıyıcı, Murat; İdilman, Ramazan; Karasu, Zeki; Akyıldız, Murat; Gençdal, Genco; Faculty Member; Doctor; School of Medicine; Koç University Hospital; 123080; N/A
    The combination of hepatitis B immunoglobulin and potent nucleos(t)ide analogs after liver transplantation is considered as the standard of care for prophylaxis against hepatitis B virus recurrence. However, the recommended doses, route of administration, and duration of HBIG administration remain unclear. Moreover, hepatitis B immunoglobulin-free prophylaxis with potent nucleos(t)ide analogs has shown promising disease outcomes in preventing hepatitis B virus recurrence. The current recommendations, produced by the Turkish Association for the Study of the Liver, Acute Liver Failure and Liver Transplantation Special Interest Group, suggest a reduced need for hepatitis B immunoglobulin administration with effective long-term suppression of hepatitis B virus replication using potent nucleos(t)ide analogs after liver transplantation.
  • Thumbnail Image
    PublicationOpen Access
    A single-center experience: liver biopsy results during a year
    (Kare Yayıncılık, 2022) Meral, Cenk Emre; Günsar, Fulya; Nart, Deniz; Yılmaz, Funda; Karasu, Zeki; Ersöz, Galip; Akarca, Ulus Salih; Gençdal, Genco; Akyıldız, Murat; Doctor; Faculty Member; School of Medicine; Koç University Hospital; N/A; 123080
    Background and aim: liver biopsy is the gold standard method for the diagnosis and treatment of liver diseases. In this study, we aimed to evaluate the results of liver biopsies performed in a year in our clinic. In addition, we also aimed if these liver biopsies could reveal the etiology of liver disease in patients with elevations of transaminases or/and alkaline phosphatase levels or liver masses. Materials and methods: patients who had liver biopsies for persistently elevated transaminases or/and alkaline phosphatase levels, protocol biopsies after liver transplantation, or liver masses in our hepatology clinic between 2011 and 2012 were included in the study. Liver biopsy decisions were made by experts during the hepatology council. Liver biopsies were previously performed using classical percutaneous liver biopsy or ultrasonography-guided Sonocan (R) liver biopsy sets. The pathology results of liver biopsies and clinical data of the matching patients were obtained from the liver biopsy record archives and patient files, respectively. Results: totally, 479 liver biopsy results (male=252, 52.6%, mean age 49 +/- 14.5 years) were evaluated in the study. Of these patients, 432 (male=228) underwent percutaneous liver biopsy and 47 (male=24) underwent Sonocan (R) needle biopsy. The most common histopathologic diagnoses in the percutaneous liver biopsy group were chronic hepatitis B (n=127, 29.4%), normal histopathological findings (n=50, 11.6% and 32 of them were protocol biopsies after liver transplantation), and nonalcoholic steatohepatitis (NASH, n=41, 9.5%). The most common histopathologic diagnoses in the Sonocan (R) group were 25 liver metastasis out of 29 liver tumors (n=25, 53.2% of all) chronic hepatitis B (n=5, 10.6%), and NASH (n=3, 6.4%). Conclusion: in this study, diversity in liver biopsy results indicates the importance of histopathological evaluation. The most prevalent pathology in the liver biopsies was chronic hepatitis B, which is the most common chronic liver disease in Turkey. The metastatic liver tumor was the most common among the liver masses.
  • Thumbnail Image
    PublicationOpen Access
    Developing new therapies for Delta hepatitis: the race is on
    (Wiley, 2021) Yurtaydın, Süleyman Cihan; Gençdal, Genco; Faculty Member; School of Medicine; Koç University Hospital; 189330; N/A